Document is current
Any future updates will be listed below
-
Authors
Spee, Blanca T. M. https://orcid.org/0000-0002-0575-5467
de Vries, Nienke M.
Zeggio, Sara
Plijnaer, Marjoke
Koksma, Jan-Jurjen
Duits, Annelien A.
Stap, Thieme
Pasman, Gert
Haeyen, Suzanne
Darweesh, Sirwan
Crone, Julia
Bloem, Bastiaan R.
Pelowski, Matthew
-
Funding
Funding for this research was provided by:
Austrian Science Fund (CM1100-B)
University of Vienna
- License Information
-
More Information
Article History
Received: 12 September 2024
Revised: 18 December 2024
Accepted: 20 December 2024
First Online: 23 January 2025
Declarations
:
: Prof. Bloem serves as the co-Editor in Chief for the Journal of Parkinson’s disease, serves on the editorial board of Practical Neurology and Digital Biomarkers, has received fees from serving on the scientific advisory board for the Critical Path Institute, Gyenno Science, MedRhythms, UCB, Kyowa Kirin and Zambon (paid to the Institute), has received fees for speaking at conferences from AbbVie, Bial, Biogen, GE Healthcare, Oruen, Roche, UCB and Zambon (paid to the Institute), and has received research support from Biogen, Cure Parkinson’s, Davis Phinney Foundation, Edmond J. Safra Foundation, Fred Foundation, Gatsby Foundation, Hersenstichting Nederland, Horizon 2020, IRLAB Therapeutics, Maag Lever Darm Stichting, Michael J Fox Foundation, Ministry of Agriculture, Ministry of Economic Affairs & Climate Policy, Ministry of Health, Welfare and Sport, Netherlands Organization for Scientific Research (ZonMw), Not Impossible, Parkinson Vereniging, Parkinson’s Foundation, Parkinson’s UK, Stichting Alkemade-Keuls, Stichting Parkinson NL, Stichting Woelse Waard, Topsector Life Sciences and Health, UCB, Verily Life Sciences, Roche and Zambon. Prof. Bloem does not hold any stocks or stock options with any companies that are connected to Parkinson’s disease or to any of his clinical or research activities. All other authors declare no conflict of interest.
